404 related articles for article (PubMed ID: 1497823)
1. Liposomes in the treatment of malignancy: a clinical perspective.
Sugarman SM; Perez-Soler R
Crit Rev Oncol Hematol; 1992; 12(3):231-42. PubMed ID: 1497823
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
3. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
4. Liposomal MTP-PE.
Gano JB; Kleinerman ES
J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
[No Abstract] [Full Text] [Related]
5. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
Kurzman ID; Shi F; Vail DM; MacEwen EG
Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
[TBL] [Abstract][Full Text] [Related]
6. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.
Kleinerman ES; Jaffe N
Prog Clin Biol Res; 1990; 343():263-79. PubMed ID: 2198583
[No Abstract] [Full Text] [Related]
7. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides.
Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL
J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109
[TBL] [Abstract][Full Text] [Related]
8. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.
Tanguay S; Bucana CD; Wilson MR; Fidler IJ; von Eschenbach AC; Killion JJ
Cancer Res; 1994 Nov; 54(22):5882-8. PubMed ID: 7954418
[TBL] [Abstract][Full Text] [Related]
9. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis.
Killion JJ; Fidler IJ
Immunomethods; 1994 Jun; 4(3):273-9. PubMed ID: 7820457
[TBL] [Abstract][Full Text] [Related]
10. Current state of liposome-complexed drugs in the treatment of cancer patients.
de Vries EG; Mulder NH; Daemen T
Ann Oncol; 1992 Jun; 3(6):419-21. PubMed ID: 1498057
[No Abstract] [Full Text] [Related]
11. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs.
Bezault J; Walsh C; Tarcsay L; Frost H; Liebes L; Furmanski P
In Vivo; 1993; 7(6A):487-91. PubMed ID: 8193265
[TBL] [Abstract][Full Text] [Related]
13. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide (MTPPE) and interferon-y (IFN-y) in experimental infection with Listeria monocytogenes.
Melissen PM; van Vianen W; Bidjai O; van Marion M; Bakker-Woudenberg IA
Biotherapy; 1993; 6(2):113-24. PubMed ID: 8398570
[TBL] [Abstract][Full Text] [Related]
14. Liposome-enhanced tumour therapy in canine mammary gland tumours.
Teske E; Rutteman GR
Tijdschr Diergeneeskd; 1993 Mar; 118 Suppl 1():32S-33S. PubMed ID: 8480312
[No Abstract] [Full Text] [Related]
15. Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases.
Schroit AJ; Fidler IJ
Prog Clin Biol Res; 1982; 102 pt A():347-55. PubMed ID: 7167445
[No Abstract] [Full Text] [Related]
16. Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages.
Utsugi T; Nii A; Fan D; Pak CC; Denkins Y; van Hoogevest P; Fidler IJ
Cancer Immunol Immunother; 1991; 33(5):285-92. PubMed ID: 1868486
[TBL] [Abstract][Full Text] [Related]
17. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
Phillips NC; Rioux J; Tsao MS
Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
[TBL] [Abstract][Full Text] [Related]
18. MTP-PE in liposomes as a biological response modifier in the treatment of cancer: current status.
Frost H
Biotherapy; 1992; 4(3):199-204. PubMed ID: 1599803
[TBL] [Abstract][Full Text] [Related]
19. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.
Gianan MA; Kleinerman ES
Cancer Biother Radiopharm; 1998 Oct; 13(5):363-8. PubMed ID: 10851426
[TBL] [Abstract][Full Text] [Related]
20. Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents.
Killion JJ; Kleinerman ES; Wilson MR; Tanaka M; Fidler IJ
Oncol Res; 1992; 4(10):413-8. PubMed ID: 1292756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
